However, this action of MALAT1 combined with HULC was abrogated in liver cancer stem cell lines transfected with pCMV6-A-GFP-HULC plus pCMV6-A-GFP-MALAT1 plus pFGP-V-RS—TRF2 or pGFP-V-RS-GFP-HULC plus pGFP-V-RS–MALAT1 plus pcDNA-CREPT (39.5%, 41.5% vs 43.7%, respectively, P > 0.05) (Fig. 8g). The gene discussed is HULC; the disease is liver cancer.